Table 2.
Drug-specific risk level and associated strength of recommendation for patients with G6PD deficiency
| Drug | Risk | Classification of Recommendation |
|---|---|---|
| Dapsone | High | Strong |
| Methylene blue | High | Moderate |
| Pegloticase | High | Strong |
| Primaquine – ≥ standard dose (0.25–0.5 mg/kg daily for 14 days) | High | Strong |
| Rasburicase | High | Strong |
| Tafenoquine | High | Strong |
| Toluidine blue | High | Moderatea |
| Nitrofurantoin | Medium | Optional |
| Primaquine – medium dose (0.75 mg/kg or 45 mg once weekly for 8 weeks) for Plasmodium vivax malaria | Medium | Strong |
| 4-aminosalicylic acid | Low-to-no | Optional |
| Aspirin ≤ 1 g/day | Low-to-no | Moderate |
| Chloramphenicol | Low-to-no | Moderate |
| Chloroquine | Low-to-no | Moderate |
| Ciprofloxacin | Low-to-no | Optional |
| Dimercaprol | Low-to-no | Optional |
| Doxorubicin | Low-to-no | Optional |
| Furazolidone | Low-to-no | Optional |
| Glyburide | Low-to-no | Optional |
| Hydroxychloroquine | Low-to-no | Moderate |
| Mafenide | Low-to-no | Optional |
| Nalidixic acid | Low-to-no | Optional |
| Norfloxacin | Low-to-no | Optional |
| Ofloxacin | Low-to-no | Optional |
| Phenazopyridine | Low-to-no | Optional |
| Primaquine – single low dose (0.25 mg/kg) for Plasmodium falciparum malaria | Low-to-no | Strong |
| Quinine | Low-to-no | Optional |
| Sulfadiazine | Low-to-no | Optional |
| Sulfadimidine | Low-to-no | Optional |
| Sulfamethoxazole | Low-to-no | Optional |
| Sulfanilamide | Low-to-no | Optional |
| Sulfasalazine | Low-to-no | Optional |
| Sulfisoxazole | Low-to-no | Optional |
| Tolbutamide | Low-to-no | Optional |
| Vitamin C | Low-to-no | Moderate |
| Vitamin K | Low-to-no | Moderate |
| Aspirin > 1 g/day | n/a | No recommendation |
| Chlorpropamide | n/a | No recommendation |
| Dabrafenib | n/a | No recommendation |
| Gliclazide | n/a | No recommendation |
| Glimepiride | n/a | No recommendation |
| Glipizide | n/a | No recommendation |
| Mepacrine | n/a | No recommendation |
| Mesalazine | n/a | No recommendation |
| Moxifloxacin | n/a | No recommendation |
| Nicorandil | n/a | No recommendation |
| Nitrofural | n/a | No recommendation |
| Probenecid | n/a | No recommendation |
| Sodium nitrite | n/a | No recommendation |
| Sulfacetamide | n/a | No recommendation |
| Tolazamide | n/a | No recommendation |
| Trametinib | n/a | No recommendation |
n/a = not applicable (not assigned a risk level)
a
Based on extrapolation from methylene blue data.